knowledge -WSS

knowledge

author：knowledge 2025-10-01 02:42:36 - browse：98187

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： FDA advisers back CAR

focus

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

UCLA team creates talking throat patch for voice disorders

FDA approves Sage Therapeutics’ rapid

Boston's new lab space is opening empty

Group behind ProMed defends move to subscription

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

How many hemophilia patients actually want gene therapy?

How one medical school became remarkably diverse

First U.S. drug developed to treat liver disease MASH is approved

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to ethically and practically extend health care to all

Medical records are filled with copy

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How I helped Pfizer think through the ethics of Viagra

hotspot

First U.S. drug developed to treat liver disease MASH is approved

CDC recommends RSV monoclonal antibody for infants

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How to ethically and practically extend health care to all

It costs an awful lot of money to give away a kidney

2 officers injured in shooting in Orlando, police say

leisure time

leisure time

focus

knowledge